Showing results (981-990 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|August 1, 1990
Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancerJ S Lee, H I Libshitz, W K Murphy, et al.
Investigational New Drugs|August 25, 2011
A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junctionDavid J Adelstein, Cristina P Rodriguez, Lisa A Rybicki, et al.
Investigational New Drugs|August 27, 2011
A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivoYong Zhang, Ahmad Ali Shaik, Chengguo Xing, et al.
Investigational New Drugs|July 13, 2011
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinomaAnthony B El-Khoueiry, Cathryn J Rankin, Edgar Ben-Josef, et al.
Investigational New Drugs|July 13, 2011
Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivoJuan R Rodrigues, Jaime Charris, Rosa Ferrer, et al.
Investigational New Drugs|February 1, 1990
Aclacinomycin A in the treatment of multiple myeloma: a Southwest Oncology Group studyC Karanes, J Crowley, L Sawkar, et al.
Investigational New Drugs|February 1, 1990
VM-26 in colorectal carcinoma: a Southwest Oncology Group studyN Oishi, T R Fleming, L Laufman, et al.
Investigational New Drugs|September 21, 2011
The effect of a novel frizzled 8-related antiproliferative factor on in vitro carcinoma and melanoma cell proliferation and invasionKristopher R Koch, Chen-Ou Zhang, Piotr Kaczmarek, et al.
Investigational New Drugs|July 6, 2011
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancerKen Kato, Keisho Chin, Takaki Yoshikawa, et al.
Investigational New Drugs|September 2, 2011
Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblastsMahmoud Alhosin, Abdulkhaleg Ibrahim, Abdelaziz Boukhari, et al.
Pageof 372